OncoMatch/Clinical Trials/NCT06072807
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
Is NCT06072807 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies non-drug interventions for breast cancer.
The goal of this interventional study is to optimize the protocol of FES PET/CT in Estrogen Receptor positive Breast cancer patients with Brain metastases. Patients will undergo MRI of the brain and FDG PET/CT brain as part of standard of care for radiation treatment planning. An additional 18F-FES PET/CT brain scan will be completed before this standard of care radiation treatment. Patients will be followed prospectively with clinical and MRI assessments per standard-of-care for a total of 12 months. Study Population: Patients with ER-positive breast cancer with biopsy proven or suspected new or recurrent brain metastases (based on standard of care MRI) planned for radiation treatment of brain lesions.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 positive
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: estrogen receptor modulator
Exception: must be discontinued for at least 8 weeks
Discontinuation of ER modulators for at least 8 weeks
Cannot have received: estrogen receptor down regulator
Exception: must be discontinued for at least 28 weeks
discontinuation of ER down regulators for at least 28 weeks
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- New York-Presbyterian/Weill Cornell Medical Center · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06072807 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior estrogen receptor modulator, estrogen receptor down regulator disqualifies patients from enrollment.
Does this trial require ESR1?
Yes, ESR1 positive is a required biomarker for enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages